Product nameAnti-GALE antibody [EPR11088(B)]
See all GALE primary antibodies
DescriptionRabbit monoclonal [EPR11088(B)] to GALE
Tested applicationsSuitable for: WB, Flow Cyt, IPmore details
Unsuitable for: ICC or IHC-P
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide corresponding to residues in Human GALE (UniProt Q14376).
- HepG2, A375, MCF7 and HeLa cell lysates; Hela cells.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20ºC.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab155997 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/10000 - 1/50000. Predicted molecular weight: 38 kDa.|
|Flow Cyt||1/10 - 1/100.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
|IP||1/10 - 1/100.|
FunctionCatalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine.
PathwayCarbohydrate metabolism; galactose metabolism.
Involvement in diseaseDefects in GALE are the cause of epimerase-deficiency galactosemia (EDG) [MIM:230350]; also known as galactosemia type 3. Clinical features include early-onset cataracts, liver damage, deafness and mental retardation. There are two clinically distinct forms of EDG. (1) A benign, or 'peripheral' form with no detectable GALE activity in red blood cells and characterized by mild symptoms. Some patients may suffer no symptoms beyond raised levels of galactose-1-phosphate in the blood. (2) A much rarer 'generalized' form with undetectable levels of GALE activity in all tissues and resulting in severe features such as restricted growth and mental development.
Sequence similaritiesBelongs to the sugar epimerase family.
- Information by UniProt
- FLJ95174 antibody
- FLJ97302 antibody
- Galactose 4 epimerase UDP antibody
All lanes : Anti-GALE antibody [EPR11088(B)] (ab155997) at 1/10000 dilution
Lane 1 : HepG2 cell lysate
Lane 2 : A375 cell lysate
Lane 3 : MCF7 cell lysate
Lane 4 : HeLa cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 38 kDa
Flow cytometric analysis of permeabilized HeLa cells labeling GALE with ab155997 at 1/10 dilution (red) compared to a rabbit IgG negative control (green).
This product has been referenced in:
- Andres LM et al. Chemical Modulation of Protein O-GlcNAcylation via OGT Inhibition Promotes Human Neural Cell Differentiation. ACS Chem Biol 12:2030-2039 (2017). Read more (PubMed: 28541657) »
- Zhu Y et al. Hepatic GALE Regulates Whole-Body Glucose Homeostasis by Modulating Tff3 Expression. Diabetes 66:2789-2799 (2017). Read more (PubMed: 28877911) »